28089587|t|Development of (111) In -labeled exendin(9-39) derivatives for single-photon emission computed tomography imaging of insulinoma
28089587|a|Insulinoma is a tumor derived from pancreatic β-cells, and the resulting hyperinsulinemia leads to characteristic hypoglycemia. Recent studies have reported the frequent overexpression of glucagon-like peptide-1 receptor (GLP-1R) in human insulinomas, suggesting that the binding of a radiolabeled compound to GLP-1R is useful for the imaging of such tumors. Exendin(9-39), a fragment peptide of exendin-3 and -4, binds GLP-1R with high affinity and acts as an antagonist. Accordingly, radiolabeled exendin(9-39) derivatives have also been investigated as insulinoma imaging probes that might be less likely to induce hypoglycemia. In this study, we synthesized a novel indium-111 ((111)In)-benzyl-diethylenetriaminepentaacetic acid ((111)In-BnDTPA) -conjugated exendin(9-39), (111)In-BnDTPA-exendin(9-39), and evaluated its utility as a probe for the SPECT imaging of insulinoma. natIn-BnDTPA-exendin(9-39) exhibited a high affinity for GLP-1R (IC50=2.5nM), stability in plasma, and a specific activity that improved following reactions with a solvent and solubilizer. Regarding the in vivo biodistribution of (111)In-BnDTPA-exendin(9-39) in INS-1 tumor -bearing mice, high uptake levels were observed in tumors (14.6%ID/g at 15min), with corresponding high tumor -to- blood (T/B), tumor -to- muscle (T/M), and tumor -to- pancreas (T/P) ratios (T/B =2.55, T/M =22.7, T/P =2.7 at 1h). The pre-administration of excess nonradioactive exendin(9-39) significantly reduced accumulation in both the tumor and pancreas (76% and 68 % inhibition, respectively) at 1h after (111)In-BnDTPA-exendin(9-39) injection, indicating that the GLP-1R mediated a majority of (111)In-BnDTPA-exendin(9-39) uptake in the tumor and pancreas. Finally, (111)In-BnDTPA-exendin(9-39) SPECT/CT studies in mice yielded clear images of tumors at 30min post-injection. These results suggest that (111)In-BnDTPA-exendin(9-39) could be a useful SPECT molecular imaging probe for the detection and exact localization of insulinomas.
28089587	15	23	(111) In	T103	UMLS:C0303403
28089587	33	46	exendin(9-39)	T103	UMLS:C0247947
28089587	47	58	derivatives	T103	UMLS:C0358514
28089587	63	113	single-photon emission computed tomography imaging	T058	UMLS:C0040399
28089587	117	127	insulinoma	T038	UMLS:C0021670
28089587	128	138	Insulinoma	T038	UMLS:C0021670
28089587	144	149	tumor	T038	UMLS:C0027651
28089587	163	181	pancreatic β-cells	T017	UMLS:C0030281
28089587	201	217	hyperinsulinemia	T038	UMLS:C0020459
28089587	242	254	hypoglycemia	T038	UMLS:C0020615
28089587	298	312	overexpression	T038	UMLS:C1514559
28089587	316	348	glucagon-like peptide-1 receptor	T103	UMLS:C0378073
28089587	350	356	GLP-1R	T103	UMLS:C0378073
28089587	361	366	human	T204	UMLS:C0086418
28089587	367	378	insulinomas	T038	UMLS:C0021670
28089587	400	407	binding	T038	UMLS:C1167622
28089587	413	434	radiolabeled compound	T103	UMLS:C0358514
28089587	438	444	GLP-1R	T103	UMLS:C0378073
28089587	463	470	imaging	T058	UMLS:C0011923
28089587	479	485	tumors	T038	UMLS:C0027651
28089587	487	500	Exendin(9-39)	T103	UMLS:C0247947
28089587	504	520	fragment peptide	T103	UMLS:C0030935
28089587	524	533	exendin-3	T103	UMLS:C0082517
28089587	538	540	-4	T103	UMLS:C0167117
28089587	542	547	binds	T038	UMLS:C1167622
28089587	548	554	GLP-1R	T103	UMLS:C0378073
28089587	589	599	antagonist	T103	UMLS:C0021643
28089587	614	652	radiolabeled exendin(9-39) derivatives	T103	UMLS:C0358514
28089587	684	694	insulinoma	T038	UMLS:C0021670
28089587	695	709	imaging probes	T103	UMLS:C0026381
28089587	746	758	hypoglycemia	T038	UMLS:C0020615
28089587	798	877	indium-111 ((111)In)-benzyl-diethylenetriaminepentaacetic acid ((111)In-BnDTPA)	T103	UMLS:C0361442
28089587	890	903	exendin(9-39)	T103	UMLS:C0247947
28089587	905	933	(111)In-BnDTPA-exendin(9-39)	T103	UMLS:C0358514
28089587	966	971	probe	T103	UMLS:C0026381
28089587	980	993	SPECT imaging	T058	UMLS:C0040399
28089587	997	1007	insulinoma	T038	UMLS:C0021670
28089587	1009	1035	natIn-BnDTPA-exendin(9-39)	T103	UMLS:C0358514
28089587	1066	1072	GLP-1R	T103	UMLS:C0378073
28089587	1100	1106	plasma	T031	UMLS:C0032105
28089587	1173	1180	solvent	T103	UMLS:C0037638
28089587	1185	1196	solubilizer	T103	UMLS:C0034760
28089587	1212	1219	in vivo	T082	UMLS:C1515655
28089587	1220	1235	biodistribution	T082	UMLS:C0037775
28089587	1239	1267	(111)In-BnDTPA-exendin(9-39)	T103	UMLS:C0358514
28089587	1271	1276	INS-1	T038	UMLS:C0021670
28089587	1277	1282	tumor	T038	UMLS:C0027651
28089587	1277	1296	tumor -bearing mice	T204	UMLS:C0025929
28089587	1303	1309	uptake	T038	UMLS:C0243144
28089587	1334	1340	tumors	T038	UMLS:C0027651
28089587	1387	1392	tumor	T038	UMLS:C0027651
28089587	1387	1403	tumor -to- blood	T033	UMLS:C0243095
28089587	1398	1403	blood	T031	UMLS:C0005767
28089587	1405	1408	T/B	T033	UMLS:C0243095
28089587	1411	1416	tumor	T038	UMLS:C0027651
28089587	1411	1428	tumor -to- muscle	T033	UMLS:C0243095
28089587	1422	1428	muscle	T017	UMLS:C0026845
28089587	1430	1433	T/M	T033	UMLS:C0243095
28089587	1440	1445	tumor	T038	UMLS:C0027651
28089587	1440	1472	tumor -to- pancreas (T/P) ratios	T033	UMLS:C0243095
28089587	1451	1459	pancreas	T017	UMLS:C0030274
28089587	1461	1464	T/P	T033	UMLS:C0243095
28089587	1474	1477	T/B	T033	UMLS:C0243095
28089587	1485	1488	T/M	T033	UMLS:C0243095
28089587	1496	1499	T/P	T033	UMLS:C0243095
28089587	1517	1535	pre-administration	T058	UMLS:C1533734
28089587	1546	1574	nonradioactive exendin(9-39)	T103	UMLS:C0247947
28089587	1597	1609	accumulation	T033	UMLS:C4055506
28089587	1622	1627	tumor	T038	UMLS:C0027651
28089587	1632	1640	pancreas	T017	UMLS:C0030274
28089587	1693	1721	(111)In-BnDTPA-exendin(9-39)	T103	UMLS:C0358514
28089587	1722	1731	injection	T058	UMLS:C1533685
28089587	1753	1759	GLP-1R	T103	UMLS:C0378073
28089587	1783	1811	(111)In-BnDTPA-exendin(9-39)	T103	UMLS:C0358514
28089587	1812	1818	uptake	T038	UMLS:C0243144
28089587	1826	1831	tumor	T038	UMLS:C0027651
28089587	1836	1844	pancreas	T017	UMLS:C0030274
28089587	1855	1883	(111)In-BnDTPA-exendin(9-39)	T103	UMLS:C0358514
28089587	1884	1900	SPECT/CT studies	T058	UMLS:C3472245
28089587	1904	1908	mice	T204	UMLS:C0025929
28089587	1933	1939	tumors	T038	UMLS:C0027651
28089587	1992	2020	(111)In-BnDTPA-exendin(9-39)	T103	UMLS:C0358514
28089587	2039	2044	SPECT	T058	UMLS:C0040399
28089587	2045	2068	molecular imaging probe	T103	UMLS:C0026381
28089587	2077	2086	detection	T058	UMLS:C1511790
28089587	2113	2124	insulinomas	T038	UMLS:C0021670